JP2023517671A5 - - Google Patents
Info
- Publication number
- JP2023517671A5 JP2023517671A5 JP2022554769A JP2022554769A JP2023517671A5 JP 2023517671 A5 JP2023517671 A5 JP 2023517671A5 JP 2022554769 A JP2022554769 A JP 2022554769A JP 2022554769 A JP2022554769 A JP 2022554769A JP 2023517671 A5 JP2023517671 A5 JP 2023517671A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- thio
- pharmaceutical composition
- inhibitor
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989041P | 2020-03-13 | 2020-03-13 | |
| US62/989,041 | 2020-03-13 | ||
| PCT/US2021/022090 WO2021183873A1 (en) | 2020-03-13 | 2021-03-12 | Sequential treatment of cancers using 6-thio-dg, checkpoint inhibitors and radiation therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023517671A JP2023517671A (ja) | 2023-04-26 |
| JP2023517671A5 true JP2023517671A5 (enExample) | 2024-03-05 |
| JP7829491B2 JP7829491B2 (ja) | 2026-03-13 |
Family
ID=77671975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554769A Active JP7829491B2 (ja) | 2020-03-13 | 2021-03-12 | ６－チオ－ｄＧ、チェックポイント阻害剤および放射線療法を使用するがんの逐次処置 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12097213B2 (enExample) |
| EP (1) | EP4117667B1 (enExample) |
| JP (1) | JP7829491B2 (enExample) |
| KR (1) | KR20220154134A (enExample) |
| CN (1) | CN115397428A (enExample) |
| AU (2) | AU2021233023B9 (enExample) |
| BR (1) | BR112022018238A2 (enExample) |
| CA (1) | CA3170930A1 (enExample) |
| DK (1) | DK4117667T3 (enExample) |
| ES (1) | ES3014683T3 (enExample) |
| FI (1) | FI4117667T3 (enExample) |
| HU (1) | HUE070513T2 (enExample) |
| IL (1) | IL296403A (enExample) |
| MX (1) | MX2022011331A (enExample) |
| PL (1) | PL4117667T3 (enExample) |
| PT (1) | PT4117667T (enExample) |
| WO (1) | WO2021183873A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210023107A1 (en) | 2018-03-22 | 2021-01-28 | The Board Of Regents Of The University Of Texas System | USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS |
| WO2025090539A1 (en) * | 2023-10-22 | 2025-05-01 | Regeneron Pharmaceuticals, Inc. | Treatment of non-small cell lung cancer with 6-thio-dg and cemiplimab |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103180463B (zh) | 2010-10-22 | 2014-12-31 | 霍夫曼-拉罗奇有限公司 | 亲硫性固相以及包含硫代羰基核苷酸的寡核苷酸的缀合物 |
| KR20150143587A (ko) | 2013-04-08 | 2015-12-23 | 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | 텔로머라제 매개된 텔로미어를 변형시키기 위한 메르캅토푸린 리보뉴클레오시드 유사체 |
| CA2991628C (en) * | 2015-07-16 | 2020-04-07 | Bioxcel Therapeutics, Inc. | A novel approach for treatment of cancer using immunomodulation |
| US20180036331A1 (en) | 2016-03-24 | 2018-02-08 | The Board Of Regents Of The University Of Texas System | Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds |
| EP3463370A4 (en) | 2016-05-27 | 2020-04-08 | The Board of Regents of The University of Texas System | 6-THIO-2'-DEOXYGUANOSINE (6-THIO-DG) RESULTS IN TELOMERASE-DEPENDENT TELOMER DYS FUNCTION AND CELL DEATH IN THERAPY-RESISTANT CANCER CELL |
| CA3035262A1 (en) | 2016-09-16 | 2018-03-22 | Tina Christine Lavranos | Antibody and checkpoint inhibitor combination therapy |
| CN117442719A (zh) * | 2017-02-21 | 2024-01-26 | 瑞泽恩制药公司 | 用于治疗肺癌的抗pd-1抗体 |
| KR20200020662A (ko) * | 2017-04-03 | 2020-02-26 | 온콜로지, 인크. | 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법 |
| US20210363243A1 (en) * | 2018-02-01 | 2021-11-25 | Merck Sharp & Dohme Corp. | Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody |
| US20210113602A1 (en) | 2018-02-28 | 2021-04-22 | The Board Of Regents Of The University Of Texas System | USE OF 6-THIO-2'-DEOXYGUANOSINE (6-THIO-dG) TO TREAT MELANOMA |
| US20210023107A1 (en) | 2018-03-22 | 2021-01-28 | The Board Of Regents Of The University Of Texas System | USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS |
-
2021
- 2021-03-12 FI FIEP21767125.4T patent/FI4117667T3/fi active
- 2021-03-12 DK DK21767125.4T patent/DK4117667T3/da active
- 2021-03-12 PT PT217671254T patent/PT4117667T/pt unknown
- 2021-03-12 WO PCT/US2021/022090 patent/WO2021183873A1/en not_active Ceased
- 2021-03-12 MX MX2022011331A patent/MX2022011331A/es unknown
- 2021-03-12 PL PL21767125.4T patent/PL4117667T3/pl unknown
- 2021-03-12 IL IL296403A patent/IL296403A/en unknown
- 2021-03-12 KR KR1020227033906A patent/KR20220154134A/ko active Pending
- 2021-03-12 HU HUE21767125A patent/HUE070513T2/hu unknown
- 2021-03-12 ES ES21767125T patent/ES3014683T3/es active Active
- 2021-03-12 JP JP2022554769A patent/JP7829491B2/ja active Active
- 2021-03-12 CA CA3170930A patent/CA3170930A1/en active Pending
- 2021-03-12 EP EP21767125.4A patent/EP4117667B1/en active Active
- 2021-03-12 BR BR112022018238A patent/BR112022018238A2/pt unknown
- 2021-03-12 CN CN202180028952.2A patent/CN115397428A/zh active Pending
- 2021-03-12 AU AU2021233023A patent/AU2021233023B9/en active Active
- 2021-03-12 US US17/200,539 patent/US12097213B2/en active Active
-
2024
- 2024-09-09 US US18/829,162 patent/US20240424013A1/en active Pending
-
2026
- 2026-07-16 AU AU2026206150A patent/AU2026206150A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021063120A5 (enExample) | ||
| JP2024526145A5 (enExample) | ||
| JP2015520753A5 (enExample) | ||
| HRP20171758T1 (hr) | Kombinacija dr5 agonista i anti-pd-1 antagonista i načini primjene | |
| JP2019519499A5 (enExample) | ||
| RU2018135317A (ru) | Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии | |
| RU2017133273A (ru) | Ингибиторы pd-1 / pd-l1 для лечения рака | |
| JP2007523862A5 (enExample) | ||
| JP2008528486A5 (enExample) | ||
| JP2022533578A5 (enExample) | ||
| JP2009539769A5 (enExample) | ||
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| JP2009506054A5 (enExample) | ||
| JP2022502399A5 (enExample) | ||
| Li et al. | Exploring hypoxic biology to improve radiotherapy outcomes | |
| JP2022510962A5 (enExample) | ||
| JP2022500479A5 (enExample) | ||
| BR112022010806A2 (pt) | Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama | |
| JP2023505687A5 (enExample) | ||
| JP2019536783A5 (enExample) | ||
| CN115429883A (zh) | 用于联合治疗的抗肿瘤药物组合物 | |
| FI4117667T3 (fi) | Syöpien jaksottainen hoito käyttäen 6-tio-dg- ja tarkistuspisteen inhibiittoreita | |
| JP2022537453A5 (enExample) | ||
| IL164783A0 (en) | Epothilone derivative for the treatment or hepatoma and other cancer diseases | |
| JP2018511642A5 (enExample) |